Article Text

Download PDFPDF

Expression of cancer-testis antigen in patients with non-small cell lung cancer and its clinical relevance
  1. Xin-Feng Chen1,2,
  2. Meng Wang1,
  3. Dong-Li Yue1,2,
  4. Jin-Yan Liu1,
  5. Lan Huang1,
  6. Feng Li1,
  7. Song Zhao3,
  8. Yu Qi3,
  9. Wei Hu3,
  10. Xiang-Nan Li3 and
  11. Yi Zhang1,2,4
  1. Aff1 grid.412633.1Biotherapy Centerthe First Affiliated Hospital of Zhengzhou University Zhengzhou China
  2. Aff2 grid.412633.1Department of Oncologythe First Affiliated Hospital of Zhengzhou University Zhengzhou China
  3. Aff3 grid.412633.1Department of Thoracic Surgerythe First Affiliated Hospital of Zhengzhou University Zhengzhou China
  4. Aff4 grid.207374.50000000121893846Department of Biological EngineeringZhengzhou University Zhengzhou China

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


Lung cancer is the most common cause of cancer-related mortality worldwide. Survival rates after non-small cell lung cancer (NSCLC) diagnosis still remain poor, despite standardization of surgery and adjuvant treatment. Cancer testis (CT) antigens as targets for immunotherapy in cancer patients have been heavily investigated. We aim to evaluate the expression of CT antigens in non-small cell lung cancer and the correlation with the clinical characteristics.


The expression of MAGE-A3, MAGE-A4, MAGE-C2 and NY-ESO-1 in fresh cancer tissues from 113 patients with non-small cell lung cancer were analyzed by RT-PCR. The expression of HLA-A2 was detected by flow cytometry.


49.6% non-small cell lung cancer samples were HLA-A2 positive. CT antigens were frequently expressed in non-small cell lung cancer. The expression percentage of each gene in cancer tissues samples were as follows: MAGE-A3, 70.8%; MAGE-A4, 46.9%; MAGE-C2, 61.1%; and NY-ESO-1, 15.0%. In all, Seventeen tissues did not express any of the CT antigens tested, 85.0% expressed at least one, 66.4% co-expressed two, 34.5% co-expressed three, 6.2% co-expressed four examined CT antigens. The percentage of samples co-expression HLA-A2 and CT genes were: MAGE-A3, 51.6%; MAGE-A4, 36.3%; MAGE-C2, 44.0%; and NY-ESO-1, 12.1%. MAGE-A3 was associated with male, smoking history, tumor stage, tumor differentiation and lymph node metastasis (P<0.05); MAGE-C2 was associated with tumor stage (P<0.05). There was no correlation MAGE-A4 or NY-ESO-1 expression with clinical characteristics such as gender, age, HLA-A2 positive, clinical stage, grade of differentiation and lymph node metastasis (P>0.05).


CT antigens might be prognostic markers and factors related to the progress of NSCLC, and also be served as the immunotherapeutic targets of NSCLC, especially in multi-antigen vaccine preparations and tumor antigen specific lymphocytes infusion.